33 results about "Advanced ovarian cancer" patented technology

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

Provided herein are methods of treating, preventing and / or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.

The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and / or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and / or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.

The invention belongs to the technical field of medicines, in particular to an injection for treating advanced ovarian cancer and a preparation method thereof.The injection is mainly prepared from the active ingredients including carboplatin, twain-20, ammonia water, a pH regulator and water for injection.The injection is stable in quality and simple in process, an impurity 1,1-cyclobutane dicarboxylic acid and other impurities do not change obviously, and the safety of the injection in clinical use is improved.

The invention belongs to the technical field of medicine, and particularly relates to an injection-purpose freeze-drying composition for treating advanced ovarian cancer and a preparing method thereof. The injection-purpose freeze-drying composition is mainly composed of active components of carboplatin, excipient, tween-80 and pH regulator. The injection-purpose freeze-drying composition preparation is stable in quality and simple in technology, in the storage process of the injection-purpose freeze-drying composition preparation, an impurity 1,1-cyclobutane dicarboxylic acid and related substances are all not obviously changed, and the clinical application safety of the preparation is improved.

A method for treating advanced epithelial ovarian cancer patients who attain a clinically-defined complete response after initial platinum / paclitaxel-based chemotherapy is described. The method involves administering a chemotherapeutic agent, such as doxorubicin, entrapped in liposomes.

The invention discloses a biflavonoid compound and application thereof, belongs to the field of natural pharmaceutical chemistry and pharmacotherapy, and particularly relates to a C-3'-C-8''-type biflavonoid compound or pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, medical application thereof, particularly application thereof as a chemotherapeuticplatinum medicine sensitizer, and a therapeutic effect on BRCA gene defect-type advanced ovarian cancer.

The invention belongs to the technical field of medicine, and particularly relates to an injection for treating advanced ovarian carcinoma and a preparation method thereof.The injection is mainly composed of an active ingredient carboplatin, tween-20, ammonia water, a pH regulator and water for injection.The preparation is stable in quality and simple in technology, a 1,1-cyclobutane dicarboxylic acid impurity and other impurities do not generate obvious changes in the storage process of the preparation, and the clinical use safety of the preparation is improved.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.

The invention discloses a use of cedar acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and the survival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinum and paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention disclosesthat yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and can be developed as a medicine for reversing the resistance of ovarian cancer to taxol. The use is characterized in that the yew antler acid, yew antler alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.